Literature DB >> 8892878

Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins.

O Orlik1, G A Splitter.   

Abstract

The mechanism of leukemogenesis and persistent lymphocytosis (PL; benign expansion of B lymphocytes) in cattle infected with bovine leukemia virus (BLV; a retrovirus closely related to human T-cell leukemia virus type 1) is unknown; however, the immune system likely plays an important role in controlling the outcome of infection. In this study, we compared T-cell competence in serologically positive alymphocytotic (AL) animals with T-cell functions in animals with progressive stages of infection, PL and tumor bearing (TB). Dramatic differences were observed in lymphocyte proliferation to recombinant proteins encoded by BLV gag (p12, p15, and p24) and env (gp30, and gp51) genes in different disease stages. Lymphocytes from AL cattle recognized an average of three of five recombinant proteins per animal. Expansion of antigen pulsed lymphocytes in interleukin-2 increased protein recognition to almost five per animal. In contrast, lymphocytes from PL and TB animals failed to recognize any BLV recombinant proteins. Short-term T-cell cultures from the PL group expanded in interleukin-2, as well as the PL and TB cells cultured in indomethacin (3 to 6 microg/ml), increased the average of recognized proteins per animal to one. Cells proliferating to BLV antigens were CD4+ T lymphocytes, as shown by cell depletion studies. The positive effect of indomethacin suggests involvement of prostaglandin E2 as a negative regulatory factor in the later stages of disease. Thus, for the first time, advancing stages of BLV infection were correlated with decreased T-cell competence, providing deeper insight into pathogenesis of retroviral infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892878      PMCID: PMC190827     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Diseases associated with HTLV-I: virus, IL-2 receptor dysregulation and redox regulation.

Authors:  J Yodoi; T Uchiyama
Journal:  Immunol Today       Date:  1992-10

2.  Humoral antibody response to bovine leukemia virus infection in cattle and sheep.

Authors:  F Bex; C Bruck; M Mammerickx; D Portetelle; J Ghysdael; Y Cleuter; M Leclercq; D Dekegel; A Burny
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

3.  Protective vaccination against bovine leukaemia virus infection by means of cell-derived vaccine.

Authors:  C Altaner; J Ban; V Altanerova; V Janik
Journal:  Vaccine       Date:  1991-12       Impact factor: 3.641

4.  T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development.

Authors:  M H Gatei; M F Good; R C Daniel; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70.

Authors:  M H Gatei; H M Naif; S Kumar; D B Boyle; R C Daniel; M F Good; M F Lavin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

6.  Augmentation of bovine leukemia virus (BLV)-specific lymphocyte proliferation responses in ruminants by inoculation with BLV env-recombinant vaccinia virus: their role in the suppression of BLV replication.

Authors:  K Ohishi; H Suzuki; Y Yasutomi; M Onuma; K Okada; S Numakunai; K Ohshima; Y Ikawa; M Sugimoto
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

7.  Detection of bovine leukemia virus proviral DNA in individual cells.

Authors:  M L Mirsky; Y Da; H A Lewin
Journal:  PCR Methods Appl       Date:  1993-05

8.  Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness.

Authors:  M Subramanyam; W G Gutheil; W W Bachovchin; B T Huber
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

9.  Bovine leukemia virus gene expression in vivo.

Authors:  L Haas; T Divers; J W Casey
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

10.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.

Authors:  A Carmichael; X Jin; P Sissons; L Borysiewicz
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

View more
  10 in total

1.  Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.

Authors:  Yamato Sajiki; Satoru Konnai; Tomohiro Okagawa; Asami Nishimori; Naoya Maekawa; Shinya Goto; Kei Watari; Erina Minato; Atsushi Kobayashi; Junko Kohara; Shinji Yamada; Mika K Kaneko; Yukinari Kato; Hirofumi Takahashi; Nobuhiro Terasaki; Akira Takeda; Keiichi Yamamoto; Mikihiro Toda; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  J Immunol       Date:  2019-07-31       Impact factor: 5.422

2.  Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus.

Authors:  D Pyeon; F J Diaz; G A Splitter
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Regulation of bovine leukemia virus tax and pol mRNA levels by interleukin-2 and -10.

Authors:  D Pyeon; G A Splitter
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

4.  B-lymphocyte proliferation during bovine leukemia virus-induced persistent lymphocytosis is enhanced by T-lymphocyte-derived interleukin-2.

Authors:  E S Trueblood; W C Brown; G H Palmer; W C Davis; D M Stone; T F McElwain
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection.

Authors:  Tomohiro Okagawa; Satoru Konnai; Ryoyo Ikebuchi; Saori Suzuki; Tatsuya Shirai; Yuji Sunden; Misao Onuma; Shiro Murata; Kazuhiko Ohashi
Journal:  Vet Res       Date:  2012-05-23       Impact factor: 3.683

6.  Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.

Authors:  Tomohiro Okagawa; Satoru Konnai; Asami Nishimori; Naoya Maekawa; Ryoyo Ikebuchi; Shinya Goto; Chie Nakajima; Junko Kohara; Satoshi Ogasawara; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Front Immunol       Date:  2017-06-07       Impact factor: 7.561

7.  Association of Transfer RNA Fragments in White Blood Cells With Antibody Response to Bovine Leukemia Virus in Holstein Cattle.

Authors:  Tasia M Taxis; Marcus E Kehrli; Rui D'Orey-Branco; Eduardo Casas
Journal:  Front Genet       Date:  2018-07-04       Impact factor: 4.599

8.  Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection.

Authors:  Tomohiro Okagawa; Satoru Konnai; Asami Nishimori; Naoya Maekawa; Shinya Goto; Ryoyo Ikebuchi; Junko Kohara; Yasuhiko Suzuki; Shinji Yamada; Yukinari Kato; Shiro Murata; Kazuhiko Ohashi
Journal:  Vet Res       Date:  2018-06-19       Impact factor: 3.683

9.  Estradiol-induced immune suppression via prostaglandin E2 during parturition in bovine leukemia virus-infected cattle.

Authors:  Yamato Sajiki; Satoru Konnai; Tomohiro Okagawa; Naoya Maekawa; Shinya Goto; Junko Kohara; Atsushi Nitanai; Hirofumi Takahashi; Kentaro Kubota; Hiroshi Takeda; Shiro Murata; Kazuhiko Ohashi
Journal:  PLoS One       Date:  2022-03-09       Impact factor: 3.240

10.  Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro.

Authors:  Ryoyo Ikebuchi; Satoru Konnai; Tomohiro Okagawa; Kazumasa Yokoyama; Chie Nakajima; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Vet Res       Date:  2013-07-22       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.